Stocks Health care CERS
NASDAQ · Health careCerus Corp (CERS)
Cerus Corp brought in $254.2M of revenue over the twelve months to September 30, 2026. It posted a net loss of $7.3M. Operating cash flow minus capital spending left $1.1M of free cash flow in fiscal 2025. At September 30, 2026 it held $16.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 2, 2026.
Key facts about Cerus Corp
- Net worth
- Cerus Corp has a market value (market cap) of $417.2M at the latest share price, and shareholders' equity of $75.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $233.8M (+16.1% year on year), with a net loss of $15.6M. Over the 12 months to September 30, 2026: revenue $254.2M, net loss $7.3M.
- Cash flow
- In fiscal 2025 operations brought in $4.8M of cash; after $3.7M of capital spending, free cash flow was $1.1M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 2, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cerus Corp's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Cerus Corp does
Cerus Corp is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker CERS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $233.8M | -$15.6M | -$0.08 | $1.1M |
| 2024 | $201.3M | -$20.9M | -$0.11 | $8.5M |
| 2023 | $186.8M | -$37.5M | -$0.21 | -$47.8M |
| 2022 | $188.3M | -$42.8M | -$0.24 | -$27.6M |
| 2021 | $159.5M | -$54.4M | -$0.32 | -$34.8M |
| 2020 | $114.2M | -$59.9M | -$0.37 | -$43.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CERS ranks in Health care
Latest SEC filings
What Cerus Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026
- November 2, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 9.5% to $57.7M versus the same quarter last year; diluted EPS $0.00 versus $0.00.
- November 2, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- July 30, 2026
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 9.5% to $57.4M versus the same quarter last year; diluted EPS -$0.01 versus -$0.03.
- July 30, 2026
- July 10, 2026
What is CERS worth? A DCF from its reported cash flow
Insider trades
What the people running Cerus Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $89.5K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 17, 2026 | Jensen ChrystalChief Legal Officer | Soldpre-planned (10b5-1) | 30,000 | $89.5K |
| July 16, 2026 | Jayaraman Vivek KChief Executive Officer | Soldpre-planned (10b5-1) | 16,666 | $52.7K |
| July 1, 2026 | Jayaraman Vivek KChief Operating Officer | Received as pay | 554,529 | - |
| June 30, 2026 | Greenman William MarinerPresident and CEO, Director | Received as pay | 192,500 | - |
| June 30, 2026 | Greenman William MarinerPresident and CEO, Director | Soldpre-planned (10b5-1) | 101,919 | $299.9K |
| June 30, 2026 | Green Kevin DennisChief Financial Officer | Received as pay | 63,600 | - |
| June 30, 2026 | Green Kevin DennisChief Financial Officer | Soldpre-planned (10b5-1) | 33,676 | $99.1K |
| June 30, 2026 | Jensen ChrystalChief Legal Officer | Received as pay | 55,000 | - |
Who owns CERS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| ARK Investment Management LLC13G, passive with 1 related filers | 8.95% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 185 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 22,215,127 | +639,708 |
| ARK Investment Management LLC | 17,932,099 | -1,229,049 |
| Vanguard Capital Management LLC | 8,563,424 | +431,646 |
| Baker Bros. Advisors LP | 6,395,431 | -3,612,914 |
| D. E. Shaw & Co., Inc. | 5,485,983 | +1,754,832 |
| Geode Capital Management, LLC | 5,119,019 | +481,579 |
| State Street Corp | 4,753,962 | +539,060 |
| Senvest Management, LLC | 4,614,061 | +500,000 |
| Sumitomo Mitsui Trust Group, Inc. | 4,139,532 | -377,074 |
| Amova Asset Management Americas, Inc. | 4,132,534 | -384,072 |
| Silvercrest Asset Management Group LLC | 4,077,187 | -164,224 |
| Two Sigma Investments, LP | 3,484,633 | +739,612 |
| Silverarc Capital Management, LLC | 3,472,737 | +296,190 |
| Wasatch Advisors LP | 3,383,899 | -1,897,237 |
| Mackenzie Financial Corp | 3,002,694 | +2,961,958 |
| Vanguard Portfolio Management LLC | 2,768,990 | +849,923 |
| Soleus Capital Management, L.P. | 2,500,000 | -8,253,700 |
| Ieq Capital, LLC | 2,406,330 | -36,911 |
| Goldman Sachs Group Inc | 2,317,802 | -450,801 |
| Aqr Capital Management LLC | 1,878,275 | -234,957 |
Insiders
11 insiders reported holding 11,502,948 shares in total, about $23.8M at the last price.
| Holder | Shares |
|---|---|
| Greenman William MarinerPresident and CEO, Director | 5,053,036 |
| Jayaraman Vivek KChief Executive Officer | 2,232,211 |
| Green Kevin DennisChief Financial Officer | 1,062,188 |
| Jensen ChrystalChief Legal Officer | 936,657 |
| Benjamin Richard JChief Medical Officer | 777,361 |
| Witney FrankDirector | 340,059 |
| Nachtsheim Jami KDirector | 268,362 |
| Bjerkholt EricDirector | 261,679 |
| Lucena AnnDirector | 232,284 |
| Shan HuaDirector | 192,386 |
Questions about CERS
What does Cerus Corp do?
Cerus Corp is a company in the Health care sector, listed on NASDAQ as CERS. Its shares trade on NASDAQ under the ticker CERS.
What is Cerus Corp's net worth?
Cerus Corp has a market value (market cap) of $417.2M at the latest share price, and shareholders' equity of $75.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cerus Corp profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $7.3M on revenue of $254.2M.
How much revenue does Cerus Corp make?
Over the twelve months to September 30, 2026 Cerus Corp reported revenue of $254.2M.
When did Cerus Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 2, 2026. It covers the period to September 30, 2026.
When is Cerus Corp's next earnings report?
Cerus Corp's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CERS with
Follow CERS
Get an email when Cerus Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cerus Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.